Related Experiment Video
Updated: May 9, 2025
Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Performance of two portable exhaled nitric oxide fraction devices compared to a "gold standard" chemiluminescence
Leo Thanikkel1, Andreas Vogt1, Srdjan J Micic1
1Department of Respiratory Medicine, University Children's Hospital Zurich, University of Zurich and Childhood Research Center, Zurich, Switzerland.
Background:
Recent guidelines for the diagnosis of asthma in schoolchildren recommend the measurement of exhaled nitric oxide fraction (F ENO) as part of the diagnostic algorithm. However, implementation may be hampered by the lack of F ENO devices that are affordable and usable in all healthcare settings. We aimed to compare the performance of two portable F ENO devices (Evernoa (EVE) and NObreath (NOB)) to a stationary "gold standard" device (CLD 88 sp (CLD)) in children.
Methods:
106 children aged 6-17 years under investigation or monitoring for asthma underwent F ENO measurements using the three devices in randomised order.
Results:
All devices showed high repeatability across a wide F ENO range (2.5-191.9 ppb). Median (interquartile range) F ENO levels were significantly lower with the portable devices (20.8 (9.5-43.5), 16 (9-36) and 22.8 (13.2-55.2) ppb for NOB, EVE and CLD, respectively; p<0.0001). Despite the proportional bias (-20% (NOB) and -40% (EVE)), both portable devices demonstrated good overall agreement with CLD (>94%) at a cut-off level of 25 ppb but lower agreement for a cut-off of 35 ppb. EVE required a greater number of attempts compared to NOB and CLD to achieve two valid measurements.
Conclusions:
Both portable devices showed limited interchangeability with the gold standard, making them less applicable for research and disease monitoring purposes. However, good overall agreement at the European Respiratory Society cut-off level (25 ppb) suggests potential as a simple and convenient screening tool in clinical settings for initial asthma diagnosis.
